March 27 (Reuters) - Walgreen WBA.O will pay more than $2.85 million to settle whistleblower allegations that the pharmacy overbilled Medicaid programs in Georgia and Massachusetts for generic medications, the U.S. Department of Justice said on Thursday.
The settlement partially resolves claims against the Walgreens Boots Alliance unit brought under the federal, Georgia and Massachusetts False Claims Act.
Walgreen pharmacies were accused of having from 2008 to 2023 submitted elevated "usual and customary" prices for some generic medications to the MassHealth and Georgia Medicaid programs, causing those programs to pay more for the medications than they should have.
(Reporting by Jonathan Stempel in New York)
((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.